Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: ARADIGM CORP. ARDM

22 Sep 2017 10:18 AM <--

10 Mar 1998 01:50 AM

Return to ARADIGM CORP. ARDM

Aradigm is involved in inhalation therapy and the new administration of drugs through the pulmonary route. One aspect is the use of insulin therapy through the latter route which eliminates the injections. Its competitor, INHL, is presently priced around $30 while ARDM is around $11 and worth a look. Check the stock talk in INHL for early thread on ARDM.